Oxford-based Coding Bio secures £9.3m Series A

Modular immunotherapies such as CAR and BiTE proteins are being developed by Oxford-based Coding Bio to provide pharmaceutical and biotechnology partners with data-driven treatment discovery. The company integrates high-throughput cellular screening with machine-learning design to identify and produce these cancer-targeting treatments.

Founded in 2020, the firm focuses on building next-generation multi-specific T-cell engagers designed for challenging indications in oncology and beyond. Its technical specialties include synthetic biology. The business operates via its website at http://coding.bio.

A £9.3m Series A investment (allotment and filing in September) constitutes the total funding raised by the business in 2026. Financial records for the year ended 30 November 2025 show the company employed 17 people at that time, while current figures from LinkedIn suggest the workforce has since expanded to 22 employees.